Rhinomed : half year results - 31 December 2021

onal use only

FY22 HALF YEARLY RESULTS

WEARABLE NASAL TECHNOLOGY PLATFORM

23 February 2022

RHINOMED CORPORATE OVERVIEW

ASX: RNO; OTCQB: RHNMF

•	Melbourne, Australia based medical device company specializing in
only	novel wearable nasal medical technology.
Our novel medical device platform technology has applications in
•
	consumer health, diagnostics and nasal drug delivery
•	Our existing CE Mark, FDA and TGA registered nasal products have been
	worn comfortably and safely since 2016 with over 30 million nightly
	user experiences.
•	Extensive IP portfolio - including over 60 patents and over 50 design
	patents.
use
Board and Management
	Mr Ron Dewhurst	Chairman
	Mr Michael Johnson	CEO and Managing Director
	Assoc Prof. John McBain	Non-Executive Director
	Mr Brent Scrimshaw	Non-Executive Director
	Dr Eric Knight	Non-Executive Director
onal	Mr Sean Slattery	CFO and Company Secretary
WEARABLE NASAL TECHNOLOGY

Key Metrics

Market Cap	~AU$62m
Current Stock price	A$0.24
Shares on issue	260 m
Top 20 Investors	77%

Top Investors

Mr Whitney George (US)	39.2%
Prof John McBain (Aust)	18.5%
Mr Ron Dewhurst (Aust)	6.8%
Citicorp Nominees	2.4%
HSBC Custody Nominees	2.2%

1

DELIVERING ON OUR STRATEGY

MEETING MILESTONES IN FY22 H1

only
Building a world
	class consumer
	health business
use	• Brand leadership via innovative
	and effective solutions
	• Curating the global snoring and
		sleep categories
	• Ecommerce excellence
	• Substantial growth on Amazon US
		- #32 in Sleep category
	• Strong review with major US and
		UK accounts with new stores
		added
onal	• Launch of new mutesnoring.com
	site

WEARABLE NASAL TECHNOLOGY

Creating a new gold standard in sampling for diagnostics

• Compelling clinical evidence
• Clear user and clinician benefits
• Value add to all players in the value chain

H1 PROGRESS

• Successful results in MCRI/RCH Rhinoswab junior trial
• Rhinoswab being integrated into State and hospital-based pathology programs
• Integration into BTNX rapid antigen test kits underway

Enhancing the

value of our technology portfolio

• Over 60 patents granted and pending
• R&D program focused on enhancing diagnostic and drug delivery capability
• Sleep program innovation underway
• Sleep and Suicide study to be published in Journal of Clinical Psychiatry

2

GROUP TRADING PERFORMANCE

TRACK RECORD OF GROWTH CONTINUES IN FY22 H1

only	$M	FY22 H1	FY21 H1	% CHANGE
Net revenues	$3,748,754	$1,945,537	92.7%
Expenses	$7,411,784	$7,745,571	(-4.4%)
Operating profit/loss	($3,227,509)	($5,484,980)	(-41.2%)
Net profit attributable to equity	(1.28)	(2.16)	(-40.7%)
owners

use	Highlights
• Gross margins from core Mute range remain strong circa 73%
• Focus on winning on Amazon and the relaunch of the new direct to consumer site -
	mutesnoring.com offsetting global decline in foot traffic in pharmacy.
• Strategic emphasis on ecommerce delivering results - online revenue contribution up
	34%
• New products lines (Rhinoswab) released to market with initial sales delivering strong
		margins
	• Increased investment in stock holdings toward the end of H1 in consumer health
		business due to Chinese new year period.
	• Investment in production set-up for Rhinoswab and Rhinoswab Junior
WEARABLE NASAL TECHNOLOGY
onal

REVENUE CONTRIBUTION

37%	Online Retail
	63%

3

FY22 H1 PERFORMANCE BUILDING OFF STRONG FY21

REVENUES GROW 92% PCP

onlyuse

onalWEARABLE NASAL TECHNOLOGY

	•	Underlying consumer health business
		gaining strong traction
+92%	•	Impact of new diagnostics/swab business
	yet to have major impact on revenues
YEAR ON YEAR	•	Both business units delivering strong gross
		margins

4